epirubicin has been researched along with Carcinoma, Small Cell Lung in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, J; Dexter, PR; He, J; Hui, SL; Jin, F; Kachroo, S; Shao, C; Zhang, Z | 1 |
| Hou, E; Lai, L; Lu, Y; Meng, W; Tan, Z; Wei, J; Zhang, X | 1 |
| Barlesi, F; Barre, P; Chatellain, P; Dayen, C; Derollez, M; Fournel, P; Herman, D; Jeannin, G; Lamy, PJ; Langlais, A; Lavole, A; Le Caer, H; Molinier, O; Morin, F; Moro-Sibilot, D; Mourlanette, P; Oster, JP; Pujol, JL; Quoix, E; Renault, A; Souquet, PJ; Zalcman, G | 1 |
| Bonanno, L; Canova, F; Carli, P; Conte, P; Favaretto, A; Pasello, G; Polo, V; Urso, L; Zago, G | 1 |
| Artal-Cortes, A; Barneto, I; Camps, C; Carrato, A; Gómez-Codina, J; González-Larriba, JL; Isla, D; Rosell, R; Safont, MJ; Sirera, R | 1 |
| Cegovnik, U; Kern, I; Korošec, P; Košnik, M; Rijavec, M; Silar, M; Triller, N | 1 |
| Guan, QL; Jiang, L; Mi, DH; Wang, J; Yang, KH | 1 |
| Cufer, T; Kern, I; Knez, L; Košnik, M; Ovčariček, T; Sadikov, A; Sodja, E | 1 |
| Dong, XJ; Li, LY; Wang, MZ; Xia, Y; Zhang, L; Zhang, XT; Zhao, J; Zhong, W | 1 |
1 review(s) available for epirubicin and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
2 trial(s) available for epirubicin and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Etoposide; Female; France; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome; Young Adult | 2015 |
Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
6 other study(ies) available for epirubicin and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medicare; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United States | 2020 |
Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma | 2015 |
Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vault Ribonucleoprotein Particles; Vincristine | 2011 |
Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Female; Gene Frequency; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma; Vincristine | 2012 |
[Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myelopoiesis; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2012 |